BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

With $56 million in fresh funding from a crossover syndicate, newly launched Longboard will develop three neuroscience programs spun out from Arena that share familiar targets with therapies previously developed by the parent company. The...
BioCentury | Oct 28, 2020
Deals

Thrive takeout by Exact Sciences could herald consolidation trend for early cancer detection companies

Thrive’s acquisition by Exact Sciences is the second in what could be a trend of big testing technology players investing in, and then buying up, early cancer detection companies. The news came along with upbeat...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships.  The round, which includes Caris Life Sciences Inc.’s first equity...
BioCentury | Oct 27, 2020
Deals

SPACs & vax: a BioCentury podcast

Once much maligned, special purpose acquisition companies have become a viable path to the public markets for top-tier biotechs this year. On the latest BioCentury This Week podcast, BioCentury editors...
BioCentury | Oct 27, 2020
Finance

With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’

Antiviral play Atea could soon join this year’s growing class of “mega-IPOs” via an offering to sell 11 million shares at $22-$24 on NASDAQ. At the midpoint, Atea would raise $253 million and be valued at...
Items per page:
1 - 10 of 13580
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202...
BioCentury | Oct 28, 2020
Deals

Out of the Arena: With $56M round, spinout Longboard to house trio of neuroscience programs

With $56 million in fresh funding from a crossover syndicate, newly launched Longboard will develop three neuroscience programs spun out from Arena that share familiar targets with therapies previously developed by the parent company. The...
BioCentury | Oct 28, 2020
Deals

Thrive takeout by Exact Sciences could herald consolidation trend for early cancer detection companies

Thrive’s acquisition by Exact Sciences is the second in what could be a trend of big testing technology players investing in, and then buying up, early cancer detection companies. The news came along with upbeat...
BioCentury | Oct 28, 2020
Finance

Oct. 27 Financial Quick Takes: Apellis-Sobi deal for C3 inhibitor; plus Primmune, Prokarium, Novartis-RegenxBio, Turning Point, Psyomics, Journey Colab

Apellis, Sobi enter territorial deal for C3 inhibitorApellis Pharmaceuticals Inc. (NASDAQ:APLS) granted Swedish Orphan Biovitrum AB (SSE:SOBI) exclusive ex-U.S. rights to systemic therapy pegcetacoplan (APL-2), an inhibitor of C3. The partners will jointly develop the...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

Delay for Spectrum due to COVID-19 travel restrictionsSpectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said FDA is deferring action on the company’s BLA for its Rolontis eflapegrastim because the agency was unable to inspect Hanmi Bioplant, the drug substance...
BioCentury | Oct 27, 2020
Finance

Tumor profiling play Caris to grow biopharma partnerships with $310M round

With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships.  The round, which includes Caris Life Sciences Inc.’s first equity...
BioCentury | Oct 27, 2020
Deals

SPACs & vax: a BioCentury podcast

Once much maligned, special purpose acquisition companies have become a viable path to the public markets for top-tier biotechs this year. On the latest BioCentury This Week podcast, BioCentury editors...
BioCentury | Oct 27, 2020
Finance

With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’

Antiviral play Atea could soon join this year’s growing class of “mega-IPOs” via an offering to sell 11 million shares at $22-$24 on NASDAQ. At the midpoint, Atea would raise $253 million and be valued at...
Items per page:
1 - 10 of 13580